Mounjaro, Zepbound shortage eases as supplies of weight loss drug rebound
Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...
Texas Attorney General Sues Insulin Makers and Pharmacy Middlemen Over High Costs
(Reuters) - The Texas attorney general has sued leading insulin manufacturers and pharmacy benefit managers (PBMs), accusing ...
Eli Lilly to Invest $4.5B for New Manufacturing & Research Plant
The Medicine Foundry, which is expected to create 400 jobs, will be situated in the LEAP Research and Innovation District in ...
Lilly weight-loss drug copycats dealt blow as shortage ends
Eli Lilly & Co.’s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the U.S., ...
Weight-Loss Drugs Are Everywhere Now. How the GLP-1 Copycats Took Over.
Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filing in the gaps.
Lilly's weight-loss drug removed from FDA's shortage list
The U.S. Food and Drug Administration removed Eli Lilly's blockbuster weight-loss and diabetes drugs from its shortage list ...
Eli Lilly’s Weight-Loss Drugs Are No Longer in Short Supply. That’s Bad for Hims & Hers.
Blockbuster drugs Zepbound and Mounjaro have come off the FDA's shortage list. Shares of Hims & Hers, which had capitalized ...
Novo Nordisk Currently Down Six Consecutive Days, on Pace for Longest Losing Streak Since September 2022 — Data Talk
Novo Nordisk A/S Sponsored ADR Class B (NVO) is currently at $115.65, down $0.83 or 0.71% --Would be lowest close since Feb. 2, 2024, when it closed at $113.70 --Currently down six consecutive days; ...
Zepbound is no longer in shortage. That could hurt off-brand weight loss drug sellers
The shortage of Eli Lilly’s (LLY) blockbuster diabetes and weight loss drugs is officially over, according to the U.S. Food ...
A mayor promises Ozempic for all and says there 'will be no more fat people' in his city
“Its patent will expire next year, and it will be available as a generic and I will introduce it to the entire public health ...
Eli Lilly's weight-loss and diabetes drugs are no longer in shortage, says FDA
The U.S. Food and Drug Administration said Eli Lilly's diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are no longer in shortage, signaling that the company has succeeded in expanding ...
FDA makes end of Zepbound, Mounjaro shortage official
Removal of Lilly’s in-demand drugs from the FDA’s shortage list ramps up pressure on the companies selling compounded ...